What Haermonics does

Haermonics B.V. is a clinical-stage medical technology company headquartered in Eindhoven, the Netherlands, developing the Haermonics Pure System, a single medical device that automates Continuous Postoperative Pericardial Flushing (CPPF) for patients recovering from open-heart surgery. The system delivers a steady flow of saline immediately upon surgical closure to prevent chest tube clogging (which occurs in up to 36% of cardiac surgery patients), reduce retained blood syndrome, and lower the rate of high-risk surgical re-exploration. The technology has been developed through three generations: a first prototype in 2013 supported by one pilot study and two RCTs, a second-generation investigational device validated in a multi-center RCT in 2020, and the commercial product in 2026 with a completed usability study. Pooled clinical evidence covers 744 patients, including a hierarchical Win Ratio analysis of 61,620 patient pairs yielding a Win Ratio of 1.73 (p<0.0001), a 40% reduction in pericardial reinterventions (p=0.044), a 34% reduction in median chest tube output at 8 hours (p<0.001), and a safety profile comparable to standard care. The company received FDA Breakthrough Device designation in 2020.

Haermonics has not yet generated commercial revenue; its business model is structured around direct enterprise sales of a medical device (likely a combination of capital equipment and consumables) to hospitals and cardiac surgery centers once the Pure System launches commercially. The GTM motion involves direct engagement with cardiothoracic surgeons and hospital procurement, supported by KOL endorsement from Dr. David Koolbergen, the inventor of CPPF and a congenital cardiothoracic surgeon at Amsterdam UMC and Leiden UMC. Strategic partnerships include Amsterdam UMC, Leiden UMC, Eindhoven University of Technology, Antonius Hospital, DEMCON (manufacturing), HeartX (2024 cardiovascular accelerator), and financial backers Invest-NL, NLC, and EU funding programs. The leadership team comprises CEO Arash Dodge, CTO Luc Koch, CFO Maarten Haast, and COO Andrea Fiorenzi, with a small disclosed management footprint that is materially smaller than the 1,001-5,000 headcount figure in some firmographic databases, suggesting a lean core organization with extensive clinical and academic collaborators.

The company's funding history is thin, with only $150,000 disclosed via the HeartX 2024 accelerator grant and historical seed-level support from NLC, UvA Ventures Holding, and ACE Incubator. The primary expansion lever is the 2026 product launch and subsequent U.S. market entry enabled by FDA Breakthrough designation, positioning the company to address a specific but high-impact failure mode in cardiac surgical recovery.

Name

Haermonics

Legal name

Haermonics B.V.

Website

https://haermonics.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Haermonics is a clinical-stage Dutch medtech company developing the Haermonics Pure System, an automated device that performs continuous postoperative pericardial flushing to prevent chest tube clogging and complications after open-heart surgery, serving hospitals and cardiac surgery centers.

Ownership category

akta.pro rank

Product category

Cardiac Surgery Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

akta.pro secondary industry

Suction, Irrigation & Fluid Management Systems (HLAHADAK)

Keywords

• Cardiac surgery devices
• Pericardial flushing systems
• Post-operative cardiac care
• Chest tube management
• Heart surgery drainage

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Haermonics Pure System (Medical Device Sales): Clinical-stage medical device company developing and commercializing the Haermonics Pure System for post-cardiac surgery care. Revenue model likely involves device sales to hospitals, potentially including capital equipment and consumables components.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Haermonics develops and commercializes the Haermonics Pure System, an automated medical device that performs Continuous Postoperative Pericardial Flushing (CPPF) immediately after cardiac surgery closure. The system delivers a steady flow of saline to chest tubes to prevent clot formation, tube obstruction, and post-operative complications such as retained blood syndrome and surgical re-exploration.

Product overview

Haermonics is a clinical-stage medtech company with a single unified product: the Haermonics Pure System. This device automates the continuous postoperative pericardial flushing (CPPF) technique that surgeons already utilize in the operating room, bringing cardiac drainage into the 21st century. The system is designed for immediate intervention upon surgical closure, maintaining steady saline flow to prevent clot formation and ensure tube patency during the critical recovery phase following open-heart surgery. The product is supported by a robust clinical evidence base including pooled data from 744 patients across pilot studies, randomized controlled trials, and multi-center studies spanning from 2013 through 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Haermonics Pure System A medical device that automates Continuous Postoperative Pericardial Flushing (CPPF) to prevent chest tube clogging and post-operative complications in cardiac surgery patients. The system maintains clear drainage by delivering a steady flow of saline to prevent clot formation from the first moment of recovery. It is intended for use by cardiac surgery teams and hospital cardiac surgery departments performing open-heart procedures.

Quantifiable outcome

• 40% reduction in pericardial reinterventions: dropping from 11.7% in control groups to 7.0% with CPPF (p=0.044)
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered core and minor.

• HeartXcoreStrategic or Co-development Partner · 1 January 2024HeartX 2024 cardiovascular accelerator program. Haermonics was selected as one of four startup healthcare companies for the program which aims to facilitate hospital pilot projects and clinical trials. The program provides $150,000 investment, access to clinical resources, and potential clinical trial opportunities.
• Amsterdam UMCcoreStrategic or Co-development PartnerAcademic medical center partnership. Dr. David Koolbergen, Inventor and Cardiothoracic Surgeon at Amsterdam UMC, serves on the advisory panel and is the inventor of the CPPF therapy.
• Leiden University Medical Center (LUMC)minorStrategic or Co-development PartnerAcademic medical center partnership for clinical research and development.
• Eindhoven University of Technology (TU/e)minorStrategic or Co-development PartnerUniversity partnership for technology research and development.
• Antonius HospitalminorStrategic or Co-development PartnerClinical partnership for research and development activities.
• LifetecminorStrategic or Co-development PartnerTechnology cluster/partnership for medical technology development in the Eindhoven region.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ConvaTec: Medical products company with surgical drainage and advanced wound care offerings. Comparable as an established player in surgical fluid management that serves the same hospital surgical departments.
• Medtronic: Global medtech leader with a broad cardiac surgery portfolio including chest drainage and perfusion products. Comparable as the dominant incumbent whose installed base and hospital relationships Haermonics must navigate to commercialize the Pure System.
• LivaNova: Cardiac surgery-focused medtech company with heart-lung machines and perfusion products. Comparable as a cardiac surgery incumbent whose hospital customers perform the very procedures the Pure System supports post-operatively.
• Edwards Lifesciences: Cardiovascular medical device leader with structural heart and critical care products. Comparable as a deep cardiac surgery specialist incumbent operating in the same surgical centers and clinician relationships.
• Becton, Dickinson and Company (BD): Major medical device manufacturer with a surgical drainage portfolio including thoracic catheters and chest drainage systems. Comparable as a broad incumbent with established hospital sales channels and bundled product offerings relevant to Haermonics' procurement process.
• Smith+Nephew: Global medical device company with wound management and surgical drainage offerings. Comparable as a broad incumbent operating in adjacent surgical drainage categories with overlapping hospital customers.

Emerging players

• Rocket Medical: Specialist manufacturer of medical drainage devices including thoracic and pleural drainage catheters. Comparable as a focused emerging competitor in chest drainage with overlapping clinical use cases in post-surgical care.

Direct peers

• Redax: Specialist manufacturer of silicone drains and chest drainage systems focused specifically on post-surgical fluid management. Comparable as a focused niche player directly competing in thoracic and cardiac drainage products.
• Getinge (Atrium Medical): Through its Atrium Medical franchise, Getinge offers chest drainage and cardiovascular surgery devices including the Advanta and Oasis product lines. Directly comparable as a leading provider of post-cardiac-surgery drainage solutions in the same hospital channel.
• Teleflex: Manufacturer of thoracic and cardiovascular drainage systems, including chest drainage catheters and accessories sold to cardiac surgery centers. Directly comparable as an established provider of post-cardiac-surgery drainage products competing for the same hospital procurement budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haermonics